This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2006 by University Hospital Muenster.
Recruitment status was:  Active, not recruiting
Hoffmann-La Roche
Information provided by:
University Hospital Muenster Identifier:
First received: February 22, 2006
Last updated: October 4, 2006
Last verified: October 2006
Psoriasis is an immuno-mediated skin disorder, which affects about 2-3% of the population worldwide. For moderate-severe forms of psoriasis systemic immunosuppression is the treatment of choice. This clinical trial was initiated to compare the safety and effectiveness of mycophenolate mofetil and cyclosporine A for the treatment of psoriasis. Patients are randomized to receive either 2.5 mg/kg BW cyclosporine A or 1 g bid mycophenolate mofetil. If after six weeks no decrease in the PASI score occures cyclosporine A doses are increased to 5 mg/kg BW for additional six weeks. In the other arm mycophenolate mofetil is increased to 1 g tid for additional six weeks.

Condition Intervention Phase
Psoriasis Drug: Cyclosporine A versus mycophenolate mofetil for psoriasis Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open, Multicenter, Randomized Clinical Trial in Patients With Moderate-Severe Psoriasis (PASI > 10) to Compare the Efficacy of Mycophenolate Mofetil Versus Cyclosporine A.

Resource links provided by NLM:

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:
  • Comparison of the two treatment arms with regard to time until psoriasis recurrence.

Secondary Outcome Measures:
  • The treatment that leads to a 75% decrease of the initial PASI score.
  • The time until complete remission.
  • The time until partial remission has occured.
  • The rate of complete remission.
  • The rate of partial remission.
  • The cumulative cyclosporine A or mycophenolate mofetil doses.

Estimated Enrollment: 50
Study Start Date: May 2000
Estimated Study Completion Date: October 2006
Detailed Description:
Not needed.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • moderate-to-severe psoriasis (PASI Score equal and greated 10)
  • written informed consent
  • for female patients effective birth control

Exclusion Criteria:

  • psoriasis arthritis
  • psoriasis palmo-plantaris
  • erythrodermic psoriasis
  • drug-induced psoriasis
  • pregnancy
  • previous treatment with cyclosporine A or mycophenolate mofetil
  • pregnancy
  • reduced liver function
  • high blood pressure
  • reduced kidney function
  • severe viral or bacterial infection
  • 2 weeks before or after vaccinations
  • innate or acquired immunodeficiency
  • severe neurologic or psychiatric symptoms
  • participation in other trials
  • other reasons voiced by the treating physician
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00295425

Nicolas Hunzelmann
Cologne, Germany
Prof. Michael Sticherling
Leipzig, Germany
Sponsors and Collaborators
University Hospital Muenster
Hoffmann-La Roche
Principal Investigator: Stefan Beissert, Professor Department of Dermatology, University Hospital Muenster, Muenster, Germany
  More Information Identifier: NCT00295425     History of Changes
Other Study ID Numbers: TALSB002
Study First Received: February 22, 2006
Last Updated: October 4, 2006

Keywords provided by University Hospital Muenster:
randomized clinical trial
cyclosporine A
mycophenolate mofetil

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Mycophenolic Acid
Mycophenolate mofetil
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on July 19, 2017